These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15819171)

  • 61. Bleeding and the new anticoagulants: strategies and concerns.
    Samama CM; Levy JH
    Anesthesiology; 2015 Feb; 122(2):236-7. PubMed ID: 25437499
    [No Abstract]   [Full Text] [Related]  

  • 62. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
    Taketomi T; Szlam F; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):106-8. PubMed ID: 18180627
    [No Abstract]   [Full Text] [Related]  

  • 63. Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII.
    Tangelder M; Long C; Emmerechts J; Jacquemin M; Peerlinck K; Vanassche T; Glazer S; Giesen P; Hoylaerts M; Verhamme P
    J Thromb Haemost; 2012 Jul; 10(7):1371-8. PubMed ID: 22540161
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation.
    Allen GA; Monroe DM; Roberts HR; Hoffman M
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S3-7. PubMed ID: 10850556
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Appearance of an antithrombin following thrombin injections in a hemophilic having presented a circulating anticoagulant].
    SOULIER JP
    Rev Hematol; 1953; 8(1):39-43. PubMed ID: 13101088
    [No Abstract]   [Full Text] [Related]  

  • 66. Fibrinopeptide A release by factor-IX concentrates and FEIBA fraction (factor eight inhibitor bypassing activity).
    Hofmann V; Straub PW
    Thromb Res; 1980 Dec 1-15; 20(5-6):623-31. PubMed ID: 6785894
    [No Abstract]   [Full Text] [Related]  

  • 67. Heparin monitoring and thrombosis.
    Glynn MF
    Am J Clin Pathol; 1979 Apr; 71(4):397-400. PubMed ID: 443197
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor.
    Fritsch P; Cvirn G; Cimenti C; Baier K; Gallistl S; Koestenberger M; Roschitz B; Leschnik B; Muntean W
    J Thromb Haemost; 2006 May; 4(5):1071-7. PubMed ID: 16689761
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Acidosis induced by carbon dioxide insufflation decreases heparin potency: a risk factor for thrombus formation.
    Gorter KA; Stehouwer MC; Van Putte BP; Vlot EA; Urbanus RT
    Perfusion; 2017 Apr; 32(3):214-219. PubMed ID: 27789847
    [TBL] [Abstract][Full Text] [Related]  

  • 70. THE HEPARIN CO-FACTOR ACTIVITY IN PLASMA AND ITS RELATION TO THE ANTICOAGULANT EFFECT OF INTRAVENOUSLY INJECTED HEPARIN.
    BLOMBAECK B; BLOMBAECK M; LAGERGREN H; OLSSON P
    Acta Physiol Scand; 1963 Aug; 58():306-18. PubMed ID: 14078650
    [No Abstract]   [Full Text] [Related]  

  • 71. Efficacy of pro- and anticoagulant strategies in plasma of patients undergoing hepatobiliary surgery.
    Bos S; van den Boom B; Ow TW; Prachalias A; Adelmeijer J; Phoolchund A; Dunsire F; Milan Z; Roest M; Heaton N; Bernal W; Lisman T
    J Thromb Haemost; 2020 Nov; 18(11):2840-2851. PubMed ID: 33124784
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stability of VIII:C in plasma: the dependence on protease activity and calcium.
    Rock GA; Cruickshank WH; Tackaberry ES; Ganz PR; Palmer DS
    Thromb Res; 1983 Mar; 29(5):521-35. PubMed ID: 6407138
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antithrombin antigen of high molecular weight associated with neoantigen in hemophilic plasma after factor IX concentrate therapy.
    Hultin MB; Abildgaard U
    Thromb Res; 1987 Jan; 45(2):175-82. PubMed ID: 3105116
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In vitro studies on the way in which the activation of factor VIII is affected in mixtures of plasma with hemophilia A plasma.
    Mingers AM
    Eur J Pediatr; 1976 Oct; 123(3):199-213. PubMed ID: 976284
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Limited factor VIIa surface localization requirement of the factor VIIa-induced overall thrombin generation in platelet-rich hemophilia A plasma.
    Persson E; Winther M
    Res Pract Thromb Haemost; 2019 Oct; 3(4):713-717. PubMed ID: 31624791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation.
    Werner MJM; Adelmeijer J; de Meijer VE; de Kleine RHJ; Scheenstra R; Bontemps STH; Reyntjens KMEM; Hulscher JBF; Porte RJ; Lisman T
    Thromb Haemost; 2020 Sep; 120(9):1240-1247. PubMed ID: 32629499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group.
    Hilgartner M; Aledort L; Andes A; Gill J
    Transfusion; 1990 Sep; 30(7):626-30. PubMed ID: 2402777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Novel therapeutic agents in the management of hemorrhage and thrombosis.
    Kempton CL; Harvey RD; Roberts HR
    Cardiovasc Hematol Agents Med Chem; 2006 Oct; 4(4):319-34. PubMed ID: 17073609
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Antithrombin activity and prolongation of thrombin time; comparative study of heparin and of some synthetic heparinoids].
    BURSTEIN M; GUINAND A
    Arch Int Pharmacodyn Ther; 1955 Jun; 102(1-2):96-104. PubMed ID: 13239250
    [No Abstract]   [Full Text] [Related]  

  • 80. [THE PHYSIOLOGIC INHIBITORS OF BLOOD COAGULATION IN PATHOLOGICALLY INCREASED COAGULABILITY IN VIVO. II. SERUM INFUSION INTO THE BLOOD STREAM].
    SCHIMPF K; CIBELIUS A; MARDINI R
    Klin Wochenschr; 1964 Jul; 42():637-40. PubMed ID: 14248608
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.